About KalVista Pharmaceuticals (NASDAQ:KALV)
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:KALV
- CUSIP: N/A
- Web: www.kalvista.com
- Market Cap: $126.46 million
- Outstanding Shares: 9,713,000
- 50 Day Moving Avg: $8.00
- 200 Day Moving Avg: $8.00
- 52 Week Range: $5.48 - $15.80
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.52
- P/E Growth: 0.00
- Annual Revenue: $625,000.00
- Price / Sales: 202.34
- Book Value: $2.75 per share
- Price / Book: 4.73
- EBITDA: ($16,210,000.00)
- Net Margins: -4,191.47%
- Return on Equity: -60.42%
- Return on Assets: -55.11%
- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 7.88%
- Quick Ratio: 7.88%
- Average Volume: 300,460 shs.
- Beta: 2.54
- Short Ratio: 11.72
Frequently Asked Questions for KalVista Pharmaceuticals (NASDAQ:KALV)
What is KalVista Pharmaceuticals' stock symbol?
KalVista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."
How were KalVista Pharmaceuticals' earnings last quarter?
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) posted its earnings results on Thursday, September, 14th. The company reported ($0.51) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.59) by $0.08. The business earned $0.10 million during the quarter. KalVista Pharmaceuticals had a negative return on equity of 60.42% and a negative net margin of 4,191.47%. View KalVista Pharmaceuticals' Earnings History.
Where is KalVista Pharmaceuticals' stock going? Where will KalVista Pharmaceuticals' stock price be in 2017?
1 brokerages have issued 12-month price targets for KalVista Pharmaceuticals' shares. Their predictions range from $27.00 to $27.00. On average, they expect KalVista Pharmaceuticals' share price to reach $27.00 in the next twelve months. View Analyst Ratings for KalVista Pharmaceuticals.
Who are some of KalVista Pharmaceuticals' key competitors?
Some companies that are related to KalVista Pharmaceuticals include Synlogic (SYBX), Mereo BioPharma Group PLC (MPH), Strongbridge Biopharma PLC (SBBP), Fortress Biotech (FBIO), Kamada (KMDA), Peregrine Pharmaceuticals (PPHM), Kadmon Holdings (KDMN), Vericel Corp (VCEL), MediWound (MDWD), Alimera Sciences (ALIM), VIVUS (VVUS), Opiant Pharmaceuticals (OPNT), Chiasma (CHMA), Cardiome Pharma Corp (CRME), Cesca Therapeutics (KOOL), Tokai Pharmaceuticals (NVUS), Ocera Therapeutics (OCRX) and Onconova Therapeutics (ONTX).
Who are KalVista Pharmaceuticals' key executives?
KalVista Pharmaceuticals' management team includes the folowing people:
- Richard Aldrich, Chairman of the Board
- Thomas Andrew Crockett, Chief Executive Officer, Director
- Benjamin L. Palleiko, Chief Financial Officer
- Christopher Yea Ph.D., Chief Development Officer
- Arnold L. Oronsky Ph.D., Director
- Joshua Resnick M.D., Director
- Rajeev Shah, Director
- Albert Cha M.D. Ph.D., Independent Director
- Edward W. Unkart CPA, Independent Director
How do I buy KalVista Pharmaceuticals stock?
Shares of KalVista Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is KalVista Pharmaceuticals' stock price today?
MarketBeat Community Rating for KalVista Pharmaceuticals (NASDAQ KALV)MarketBeat's community ratings are surveys of what our community members think about KalVista Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of KalVista Pharmaceuticals stock can currently be purchased for approximately $13.02.
Earnings History for KalVista Pharmaceuticals (NASDAQ:KALV)Earnings History by Quarter for KalVista Pharmaceuticals (NASDAQ KALV)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|9/14/2017||Q1 2018||($0.59)||($0.51)||$0.10 million||View||N/A|
|7/27/2017||Q4 2017||($0.43)||$0.11 million||View||N/A|
|11/8/2016||Q3 2016||($0.21)||($0.09)||$0.01 million||View||N/A|
|11/11/2015||Q315||($0.26)||($0.19)||$0.01 million||$0.01 million||View||Listen|
|8/11/2015||Q215||($0.21)||($0.37)||$0.01 million||$0.01 million||View||Listen|
Earnings Estimates for KalVista Pharmaceuticals (NASDAQ:KALV)
Current Year EPS Consensus Estimate: $-2.49 EPS
Next Year EPS Consensus Estimate: $-2.88 EPS
Dividend History for KalVista Pharmaceuticals (NASDAQ:KALV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for KalVista Pharmaceuticals (NASDAQ:KALV)
Insider Ownership Percentage: 49.10%Insider Trades by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)
Institutional Ownership Percentage: 75.66%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/12/2017||Holdings A/S Novo||Major Shareholder||Sell||2,725,283||$9.64||$26,271,728.12|| |
|10/12/2017||Rajeev M Shah||Director||Buy||850,000||$8.50||$7,225,000.00|| |
|9/15/2017||Holdings A/S Novo||Major Shareholder||Sell||176,647||$7.21||$1,273,624.87|| |
|9/14/2017||Holdings A/S Novo||Major Shareholder||Sell||10,000||$8.05||$80,500.00|| |
|9/13/2017||Holdings A/S Novo||Major Shareholder||Sell||25,900||$8.02||$207,718.00|| |
|12/30/2015||David Renzi||CEO||Sell||10,000||$3.70||$37,000.00|| |
|4/14/2015||Acmp Iv Llc||Major Shareholder||Buy||877,500||$5.00||$4,387,500.00|| |
|4/14/2015||Albert Cha||Director||Buy||1,012,500||$5.00||$5,062,500.00|| |
Headline Trends for KalVista Pharmaceuticals (NASDAQ:KALV)
Latest Headlines for KalVista Pharmaceuticals (NASDAQ:KALV)
Loading headlines, please wait.
KalVista Pharmaceuticals (KALV) Chart for Monday, October, 23, 2017